Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy.

Autor:	Ruiz-Bañobre J; Medical Oncology Department, Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain.; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago de Compostela, CIBERONC, Santiago de Compostela, Spain., Areses-Manrique MC; Medical Oncology Department, Complejo Hospitalario Universitario de Ourense, Ourense, Spain., Mosquera-Martínez J; Medical Oncology Department, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain., Cortegoso A; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago de Compostela, CIBERONC, Santiago de Compostela, Spain.; Medical Oncology Department, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain., Afonso-Afonso FJ; Medical Oncology Department, Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain., de Dios-Álvarez N; Medical Oncology Department, Complejo Hospitalario Universitario de Vigo, Vigo, Spain., Fernández-Núñez N; Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain., Azpitarte-Raposeiras C; Medical Oncology Department, Complejo Hospitalario de Pontevedra, Pontevedra, Spain., Amenedo M; Medical Oncology Department, Centro Oncológico de Galicia, A Coruña, Spain., Santomé L; Medical Oncology Department, Hospital Povisa, Vigo, Spain., Fírvida-Pérez JL; Medical Oncology Department, Complejo Hospitalario Universitario de Ourense, Ourense, Spain., García-Campelo R; Medical Oncology Department, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain., García-González J; Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago de Compostela, CIBERONC, Santiago de Compostela, Spain.; Medical Oncology Department, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain., Casal-Rubio J; Medical Oncology Department, Complejo Hospitalario Universitario de Vigo, Vigo, Spain., Vázquez S; Medical Oncology Department, Hospital Universitario Lucus Augusti, Lugo, Spain.
Jazyk:	angličtina
Zdroj:	Translational lung cancer research [Transl Lung Cancer Res] 2019 Dec; Vol. 8 (6), pp. 1078-1085.
DOI:	10.21037/tlcr.2019.11.07
Abstrakt:	The lung immune prognostic index (LIPI) has been proposed as a new categorical blood-based biomarker to select advanced non-small cell lung cancer (NSCLC) patients for anti-programmed cell death-1 (PD-1) or programmed death ligand 1 (PD-L1) therapy. In this study, we investigate for the first time to the best of our knowledge the prognostic and predictive utility of the LIPI in a multicenter nivolumab monotherapy-based cohort. We retrospectively analyzed the influence of the baseline LIPI on overall survival (OS), progression-free survival (PFS), disease control rate (DCR), and overall response rate (ORR) among 153 patients of a cohort of 188 advanced NSCLC patients treated with nivolumab in the second line of therapy or beyond. Worse LIPI was significantly associated with shorter OS in univariate [hazard ratio (HR) =3.12, 95% confidence interval (CI), 2.12-4.60; P<0.0001] and multivariate (HR =3.67, 95% CI, 1.96-6.86; P<0.0001) analyses. Worse LIPI was associated with shorter PFS (HR =1.45, 95% CI, 1.05-2.03; P=0.03), but this correlation did not reach statistical significance in multivariate analysis (HR =1.49, 95% CI, 0.94-2.38; P=0.09). Worse LIPI was associated with lower DCR in univariate [odds ratio (OR) =0.41, 95% CI, 0.24-0.70; P=0.001] and multivariate (OR =0.44, 95% CI, 0.25-0.78; P=0.005) analyses. This study confirms the utility of the LIPI in prognostication and disease control prediction in advanced NSCLC patients treated with nivolumab in the second line of therapy or beyond. Competing Interests: Conflicts of Interest: Juan Ruiz-Bañobre - Travel, Accommodations, Expenses: Bristol-Myers Squibb, Merck Sharp & Dohme, Ipsen, PharmaMar. Speakers’ Bureau: Roche. María C. Areses-Manrique - Consulting or Advisory Role: Roche/Genentech, AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Takeda, Lilly, Bristol-Myers Squibb. Francisco J. Afonso-Afonso - Consulting or Advisory Role: Merck Sharp & Dohme, AstraZeneca, Bristol-Myers Squibb, Pfizer, Novartis, Takeda, Boehringer Ingelheim. Travel, Accommodations, Expenses: Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer. Margarita Amenedo - Consulting or Advisory Role: Boehringer Ingelheim, Clovis Oncology. Speakers' Bureau: AstraZeneca; PharmaMar, Roche, Pierre Fabre, Lilly. Travel, Accommodations, Expenses: Roche, Lilly. José Luis Fírvida-Pérez - Consulting or Advisory Role: Roche/Genentech, AstraZeneca, Boehringer Ingelheim, MSD Oncology, Takeda, Lilly, Bristol-Myers Squibb. Rosario García-Campelo - Consulting or Advisory Role: Roche/Genentech, MSD Oncology, AstraZeneca, Bristol-Myers Squibb, Pfizer, Novartis, Takeda, Boehringer Ingelheim. Speakers’ Bureau: Roche, AstraZeneca, Bristol-Myers Squibb, Pfizer, Novartis, Takeda, Boehringer Ingelheim, MSD Oncology. Jorge García-González - Consulting or Advisory Role: Bristol-Myers Squibb, MSD Oncology, Roche/Genentech, Lilly, Boehringer Ingelheim, AstraZeneca, Pierre Fabre. Travel, Accommodations, Expenses: Bristol-Myers Squibb, Merck Sharp & Dohme, Roche/Genentech. Sergio Vázquez - Consulting or Advisory Role: Pfizer, Astellas, Janssen, MSD Oncology, Bayer, Roche, Bristol-Myers Squibb, Boehringer Ingelheim, AstraZeneca, Ipsen, Novartis, Eusa Pharma, Eisai and Sanofi. Speakers’ Bureau: Lilly, Astellas, Bayer, Roche, Boehringer Ingelheim, Ipsen, Novartis, AstraZeneca and Sanofi. Travel, Accommodations, Expenses: Pfizer, Roche and AstraZeneca. The other authors have no conflicts of interest to declare. (2019 Translational Lung Cancer Research. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu